中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Clinical effect of transcatheter arterial chemoembolization combined with local thermal ablation in treatment of large hepatocellular carcinoma and related influencing factors

DOI: 10.3969/j.issn.1001-5256.2019.01.018
Research funding:

 

  • Published Date: 2019-01-20
  • Objective To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with local thermal ablation in the treatment of large hepatocellular carcinoma (HCC) .Methods A retrospective analysis was performed for the clinical data of134 patients with large HCC who underwent TACE combined with local thermal ablation in our center from January 2010 to September 2016.In all patients, 75 underwent TACE combined with microwave ablation and 59 underwent TACE combined with radiofrequency ablation.The effect of ablation (complete ablation and partial ablation) was evaluated, and follow-up was performed to observe the recurrence of intrahepatic tumor in patients with complete ablation.The chi-square test and logistic regression analysis were used to evaluate the influencing factors for the effect of ablation, and the Kaplan-Meier survival analysis and the Cox proportional hazards model were used to analyze recurrence-free survival and related influencing factors.Results Of all patients, 88 achieved complete ablation and 46 patients achieved partial ablation, resulting in a complete ablation rate of 65.7%.The logistic regression analysis showed that presence of portal vein tumor thrombus (odds ratio[OR]=5.051, P=0.017) , incomplete tumor capsule (OR=4.199, P=0.007) , and dangerous location of tumor (OR=4.967, P=0.001) were independent risk factors for the effect of ablation.The patients with complete ablation had a median recurrencefree survival of 17.41±2.73 months and the 1-, 3-, and 5-year recurrence-free survival rates were 61.4%, 23.3%, and 17.7%, respectively;the multivariate analysis showed that multiple tumors (OR=1.708, P=0.041) was an independent risk factor.There were no significant differences between TACE combined with microwave ablation and TACE combined with radiofrequency ablation in the effect of ablation (χ2=2.431, P=0.119) and tumor recurrence (χ2=3.292, P=0.070) .ConclusionPresence of portal vein tumor thrombus, tumor capsule integrity, and tumor location are important influencing factors for the effect of ablation in patients with large HCC.For patients with complete ablation, the number of tumors can be used to assess the risk of intrahepatic tumor recurrence.

     

  • [1]FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J].The Lancet, 2018, 391 (10127) :1301-1314.
    [2]BALOGH J, VICTOR DR, ASHAM EH, et al.Hepatocellular carcinoma:A review[J].J Hepatocell Carcinoma, 2016, 3:41-53.
    [3]GUIMARAES M, UFLACKER R.Locoregional therapy for hepatocellular carcinoma[J].Clin Liver Dis, 2011, 15 (2) :395-421.
    [4]SHI J, SUN Q, WANG Y, et al.Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria[J].J Gastroenterol Hepatol, 2014, 29 (7) :1500-1507.
    [5]HOCQUELET A, BALAGEAS P, LAURENT C, et al.Radiofrequency ablation versus surgical resection for hepatocellular carcinoma within the Milan criteria:A study of 281 Western patients[J].Int J Hyperthermia, 2015, 31 (7) :749-757.
    [6]LEE DH, LEE JM, LEE JY, et al.Radiofrequency ablation of hepatocellular carcinoma as first-line treatment:Long-term results and prognostic factors in 162 patients with cirrhosis[J].Radiology, 2014, 270 (3) :900-909.
    [7]GUO XD, SUN SS, LI WD, et al.Effects of transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation on patients with intermediate stage primary liver cancer[J/CD].Chin J Liver Dis:Electronic Edition, 2018, 10 (2) :30-36. (in Chinese) 郭晓笛, 孙莎莎, 李文东, 等.肝动脉化疗栓塞术联合射频消融术治疗中期原发性肝癌患者的疗效[J/CD].中国肝脏病杂志:电子版, 2018, 10 (2) :30-36.
    [8]XU Y, SHEN Q, WANG N, et al.Percutaneous microwave ablation of 5-6 cm unresectable hepatocellular carcinoma:Local efficacy and long-term outcomes[J].Int J Hyperthermia, 2016.[Epub ahead of print]
    [9]YIN XY, XIE XY, LU MD, et al.Percutaneous thermal ablation of medium and large hepatocellular carcinoma:Long-term outcome and prognostic factors[J].Cancer, 2009, 115 (9) :1914-1923.
    [10]ZHAI B.Strategy and prospect of thermal ablation for treatment of large hepatocellular carcinoma[J/CD].Eletronic JLiver Tumor, 2017, 4 (4) :13-16. (in Chinese) 翟博.大肝癌热消融治疗策略及展望[J/CD].肝癌电子杂志, 2017, 4 (4) :13-16.
    [11]CHEN WY, REN N.Advances in molecular targeted therapy for hepatocellular carcinoma[J].J Clin Hepatol, 2018, 34 (7) :1387-1394. (in Chinese) 陈万勇, 任宁.肝细胞癌分子靶向治疗进展[J].临床肝胆病杂志, 2018, 34 (7) :1387-1394.
    [12]TAKAKI H, YAMAKADO K, URAKI J, et al.Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm[J].J Vasc Interv Radiol, 2009, 20 (2) :217-224.
    [13]LIM C, MISE Y, SAKAMOTO Y, et al.Above 5 cm, size does not matter anymore in patients with hepatocellular carcinoma[J].World J Surg, 2014, 38 (11) :2910-2918.
    [14]DELIS SG, BAKOYIANNIS A, TASSOPOULOS N, et al.Hepatic resection for hepatocellular carcinoma exceeding Milan criteria[J].Surg Oncol, 2010, 19 (4) :200-207.
    [15]CHANG YJ, CHUNG KP, CHANG YJ, et al.Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas[J].Br J Surg, 2016, 103 (11) :1513-1520.
    [16]ZHANG W, TAN Y, JIANG L, et al.Liver resection associated with better outcomes for single large hepatocellular carcinoma located in the same section[J].Medicine (Baltimore) , 2017, 96 (10) :e6246.
    [17]SONG SH, GUO J, ZOU C.Factors influencing postoperative recurrence in patients with primary liver cancer after hepatectomy[J].J Pract Hepatol, 2017, 20 (2) :203-206. (in Chinese) 宋书红, 郭俊, 邹灿.肝癌手术切除术后复发相关因素分析[J].实用肝脏病杂志, 2017, 20 (2) :203-206.
    [18]IEZZI R, POMPILI M, LA TORRE MF, et al.Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma[J].Dig Liver Dis, 2015, 47 (3) :242-248.
    [19]SHI M, ZHANG CQ, ZHANG YQ, et al.Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin[J].World J Surg, 2004, 28 (4) :376-381.
    [20]REN ZG.Immunotherapy for hepatocellular carcinoma[J].JClin Hepatol, 2018, 34 (7) :1371-1373. (in Chinese) 任正刚.肝细胞癌的免疫治疗[J].临床肝胆病杂志, 2018, 34 (7) :1371-1373.
    [21]XU LF, SUN HL, CHEN YT, et al.Large primary hepatocellular carcinoma:Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy[J].J Gastroenterol Hepatol, 2013, 28 (3) :456-463.
    [22]BIOLATO M, MARRONE G, RACCO S, et al.Transarterial chemoembolization (TACE) for unresectable HCC:A new life begins?[J].Eur Rev Med Pharmacol Sci, 2010, 14 (4) :356-362.
    [23]TANG C, SHEN J, FENG W, et al.Combination therapy of radiofrequency ablation and transarterial chemoembolization for unresectable hepatocellular carcinoma:A retrospective study[J].Medicine (Baltimore) , 2016, 95 (20) :e3754.
    [24]CHANG P, ZHANG HY, XIAO M.Efficacy of transcatheter arterial chemoembolization alone or combined with microwave ablation in treatment of primary large liver cancer:A comparetive analysis[J].J Clin Hepatol, 2015, 31 (6) :880-885. (in Chinese) 常鹏, 张洪义, 肖梅.单纯经肝动脉化疗栓塞术及其联合微波消融治疗原发性大肝癌的疗效对比分析[J].临床肝胆病杂志, 2015, 31 (6) :880-885.
  • Relative Articles

    [1]Huaqiang ZHANG, Lixin LIU, Xiaohong GUO. Association of nonalcoholic fatty liver disease with the risk of colorectal adenoma and colorectal cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(7): 1619-1625. doi: 10.3969/j.issn.1001-5256.2021.07.028
    [2]Qiaohong LIU, Yu ZHAO, Yiyang HU. Effect of diet on enterotype-related gut microbiota in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 939-942. doi: 10.3969/j.issn.1001-5256.2021.04.046
    [3]Juan PENG, Liangping LI. Mechanism of action of estrogen and its receptor in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 467-470. doi: 10.3969/j.issn.1001-5256.2021.02.046
    [4]Jinhong TANG, Long WANG. Research advances in the association between nonalcoholic fatty liver disease and colorectal adenomatous polyps[J]. Journal of Clinical Hepatology, 2021, 37(11): 2672-2675. doi: 10.3969/j.issn.1001-5256.2021.11.040
    [5]Yalan LEI, Jian BI, Jingwei MAO. Impact of nonalcoholic fatty liver disease on intestinal immune cells[J]. Journal of Clinical Hepatology, 2021, 37(11): 2667-2671. doi: 10.3969/j.issn.1001-5256.2021.11.039
    [6]Shenglan ZENG, Rongzhen ZHANG, Na WANG, Tingshuai WANG, Liting TAN, Dewen MAO. Effect of diet-gut microbiota axis on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2676-2679. doi: 10.3969/j.issn.1001-5256.2021.11.041
    [7]Chenlu ZHAO, Wenxia ZHAO. Influence of estrogen deficiency on metabolic associated fatty liver disease in postmenopausal women[J]. Journal of Clinical Hepatology, 2021, 37(7): 1708-1712. doi: 10.3969/j.issn.1001-5256.2021.07.049
    [8]Tian TIAN, Wenwei HU, Xue LI, Jie WU, Dan ZHANG, Changzheng LI. Association between thyroxine level and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2357-2363. doi: 10.3969/j.issn.1001-5256.2021.10.020
    [9]Xiangqian HUANG, Xiaomeng YAN, Mingda ZHANG, Jing WU, Jianhong CHEN. Association between nonalcoholic fatty liver disease and colorectal neoplasms[J]. Journal of Clinical Hepatology, 2021, 37(12): 2947-2950. doi: 10.3969/j.issn.1001-5256.2021.12.045
    [10]SUN MengYuan, XIANG XiaoXing. Role of gut microbiota and bile acid pathway in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(12): 2831-2834. doi: 10.3969/j.issn.1001-5256.2020.12.040
    [11]Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
    [12]Hui DengCheng, Sun MingYu. Association between nonalcoholic fatty liver disease and gut microbiota based on the theory of gut-liver axis[J]. Journal of Clinical Hepatology, 2020, 36(7): 1627-1630. doi: 10.3969/j.issn.1001-5256.2020.07.039
    [13]Zhang Dan, Zhou Bo, Deng Yi, Wen Yu, Lu: JunYan, Wang JinXiang, Geng ZuoTao, Luo SuFeng, Ying YunYan, Wen DaiYan, Shi ChunJing, Pu GuangYu, Jiang Xin, Ma LanQing. Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 829-834. doi: 10.3969/j.issn.1001-5256.2020.04.024
    [14]Chuan LiXue, Chang Jiang, Zhao JinHan, Li LuoHua, Yang XuYao, Yu Di. Association between nonalcoholic fatty liver disease and colorectal adenomatous polyps[J]. Journal of Clinical Hepatology, 2020, 36(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2020.06.022
    [15]Feng Gong, He Na, Mi Man, Li XuePing, Liu ManLing, Fan LiPing, Niu ChunYan. Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(4): 835-839. doi: 10.3969/j.issn.1001-5256.2019.04.025
    [16]Liu SiFu, Xie ZhengYuan. Association between nonalcoholic fatty liver disease and colorectal tumors[J]. Journal of Clinical Hepatology, 2019, 35(9): 2091-2094. doi: 10.3969/j.issn.1001-5256.2019.09.046
    [17]Zhang XiaXia, Xu HongTuan, Xu YouQing. The natural history and clinical features of nonalcoholic fatty liver disease-related cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 24-26. doi: 10.3969/j.issn.1001-5256.2018.01.004
    [18]Liu JiaQi, Zhou ShaoMing. Research advances in intestinal flora in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2453-2456. doi: 10.3969/j.issn.1001-5256.2017.12.045
    [19]Lu Xu, Han Tao, Tian Yao, Lu BoWei, Zhang Qian. Research progress in roles of gut microbiota and bile acid metabolism in development and progression of NAFLD[J]. Journal of Clinical Hepatology, 2014, 30(11): 1225-1228. doi: 10.3969/j.issn.1001-5256.2014.11.034
    [20]Zhu Peng, Xu Zong, Wang YuMing. World Gastroenterology Organisation global guidelines:nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2014, 30(9): 842-845. doi: 10.3969/j.issn.1001-5256.2014.09.002
  • Cited by

    Periodical cited type(3)

    1. 黄嘉卿. NNN-链接护理模式对血小板减少症患者睡眠质量及自我感受影响研究. 世界睡眠医学杂志. 2024(02): 378-381 .
    2. 赵静雯,王溶,杨隽芃. 艾尔巴韦格拉瑞韦片治疗继发性丙型肝炎病毒感染的效果观察. 中国处方药. 2023(04): 97-99 .
    3. 戴兆东. 直接抗病毒药物对丙型肝炎肝硬化患者的临床疗效分析. 抗感染药学. 2023(12): 1308-1311 .

    Other cited types(0)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 3.5 %FULLTEXT: 3.5 %META: 93.1 %META: 93.1 %PDF: 3.5 %PDF: 3.5 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.6 %其他: 7.6 %其他: 0.7 %其他: 0.7 %China: 0.7 %China: 0.7 %India: 0.2 %India: 0.2 %United Kingdom: 0.5 %United Kingdom: 0.5 %[]: 0.3 %[]: 0.3 %上海: 2.1 %上海: 2.1 %中卫: 0.2 %中卫: 0.2 %中央邦: 0.5 %中央邦: 0.5 %中山: 0.2 %中山: 0.2 %佛山: 0.3 %佛山: 0.3 %北京: 5.9 %北京: 5.9 %南京: 0.7 %南京: 0.7 %南宁: 0.2 %南宁: 0.2 %吉林: 0.7 %吉林: 0.7 %密蘇里城: 0.2 %密蘇里城: 0.2 %廊坊: 0.2 %廊坊: 0.2 %张家口: 2.0 %张家口: 2.0 %成都: 0.2 %成都: 0.2 %扬州: 0.2 %扬州: 0.2 %新乡: 0.2 %新乡: 0.2 %昆明: 0.2 %昆明: 0.2 %杭州: 1.2 %杭州: 1.2 %柳州: 0.5 %柳州: 0.5 %武汉: 0.8 %武汉: 0.8 %石家庄: 0.3 %石家庄: 0.3 %芒廷维尤: 32.5 %芒廷维尤: 32.5 %芝加哥: 0.7 %芝加哥: 0.7 %莫斯科: 0.8 %莫斯科: 0.8 %衡水: 0.2 %衡水: 0.2 %西宁: 36.7 %西宁: 36.7 %西安: 0.2 %西安: 0.2 %诺沃克: 0.3 %诺沃克: 0.3 %长春: 0.8 %长春: 0.8 %长沙: 0.8 %长沙: 0.8 %长治: 0.2 %长治: 0.2 %青岛: 0.3 %青岛: 0.3 %鞍山: 0.2 %鞍山: 0.2 %其他其他ChinaIndiaUnited Kingdom[]上海中卫中央邦中山佛山北京南京南宁吉林密蘇里城廊坊张家口成都扬州新乡昆明杭州柳州武汉石家庄芒廷维尤芝加哥莫斯科衡水西宁西安诺沃克长春长沙长治青岛鞍山

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2030) PDF downloads(345) Cited by(3)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return